|Bid||0.5115 x 1800|
|Ask||0.5132 x 800|
|Day's Range||0.5072 - 0.5184|
|52 Week Range||0.4800 - 3.2600|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.38|
At the start of 2017, listener Arlo added 2016’s worst-performing Rule Breaker stocks to his portfolio. Here's what happened next.
Four stocks have been lined up for today's assessment, and they are: Calithera Biosciences Inc. (CALA), Cara Therapeutics Inc. (CARA), Celgene Corp. (CELG), and Celldex Therapeutics Inc. (CLDX). Shares in South San Francisco, California headquartered Calithera Biosciences Inc. jumped 5.53%, ending Wednesday's trading session at $5.25. The stock recorded a trading volume of 552,298 shares, which was higher than its three months average volume of 426,620 shares.
Celldex Therapeutics (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
--CDX-3379 also featured in a“ clinical trials in progress” presentation--. HAMPTON, N.J., June 02, 2018-- Celldex Therapeutics, Inc. today presented two programs at the 2018 American Society of Clinical ...
HAMPTON, N.J., June 01, 2018-- Celldex Therapeutics, Inc. announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will present a corporate overview at the Jefferies 2018 ...
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
HAMPTON, N.J., May 16, 2018-- Celldex Therapeutics, Inc. announced today that two abstracts will be presented at the 2018 American Society of Clinical Oncology Annual Meeting being held June 1-5, 2018 ...
Celldex Therapeutics Inc (NASDAQ:CLDX), a US$104.06M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...
Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.
The Hampton, New Jersey-based company said it had a loss of 84 cents per share. Losses, adjusted for asset impairment costs, came to 19 cents per share. The results fell short of Wall Street expectations. ...
HAMPTON, N.J., May 10, 2018-- Celldex Therapeutics, Inc. today reported business and financial highlights for the first quarter ended March 31, 2018.. “Celldex has made considerable progress on an important ...
Celldex Therapeutics, Inc. (CLDX) today announced promising early data from an investigator-initiated pilot study evaluating the combination of CDX-301 and stereotactic body radiotherapy (SBRT) in patients with advanced non-small cell lung cancer (NSCLC). CDX‑301 (recombinant human Flt3 ligand) is a potent hematopoietic cytokine that uniquely expands dendritic cells and hematopoietic stem cells.
NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
NEW YORK, NY / ACCESSWIRE / April 17, 2018 / Shares of Celldex fell to record lows on Monday after its triple negative breast cancer drug candidate didn't meet endpoints in a phase 2b trial. The company ...